超越基因型:预测双等位基因穿孔素变异携带者疾病风险的挑战
该研究结合HLH网络登记库与UK Biobank数据,评估PRF1 A91V/pLOF基因型个体的疾病外显率和临床结局。登记库中52例A91V/pLOF个体39例(72%)出现FHL2相关表现,平均发病年龄20岁;而家族筛查发现的14例中仅1例有症状,UK Biobank中21例携带者至73岁无一发生HLH。基因型与功能数据均不能预测疾病表现。
要点
- 登记库52例A91V/pLOF中39例(72%)有FHL2表现,平均发病年龄20岁。
- 家族筛查14例A91V/pLOF中仅1例有症状,UK Biobank 21例携带者至73岁无HLH发生。
- 功能数据(穿孔素表达或细胞毒性)未能预测疾病表现。
核心结论
- PRF1 A91V/pLOF携带者的疾病外显率和严重程度存在显著变异,基因型、功能数据与临床结局之间无明确关联。
- 该复杂性凸显了基因筛查的挑战,并强调对无症状携带者进行预防性HSCT需谨慎的临床决策。
研究设计与样本
- 研究结合HLH网络登记库的临床与功能数据以及UK Biobank数据,评估疾病外显率和临床结局。
- 登记库中A91V/pLOF基因型个体52例,家族筛查发现A91V/pLOF个体14例(平均年龄29岁),UK Biobank 20万参与者中鉴定出A91V/pLOF携带者21例。
主要发现
- 登记库52例A91V/pLOF个体中39例(72%)出现FHL2相关表现,平均发病年龄20岁。
- 登记库中4例患者疾病复发,15例接受移植,14例死亡。
- 家族筛查发现的14例A91V/pLOF个体中仅1例有症状。
- UK Biobank中21例A91V/pLOF携带者(其中12例基因型与有症状的登记库患者相同)至73岁无一发生HLH。
- 提前终止pLOF等位基因似乎比错义变异外显率更高,但包括穿孔素表达或细胞毒性的功能数据未能预测疾病表现。
临床怎么用
- 作者强调对无症状携带者进行预防性HSCT需谨慎的临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic screening for severe congenital immunohematological diseases offers potential for early intervention, particularly through preemptive allogeneic hematopoietic stem cell transplantation (HSCT). However, the clinical value of such screening depends on precise prognostic predictions based on genotype-phenotype correlations and/or functional confirmation. We investigated familial hemophagocytic lymphohistiocytosis type 2 (FHL2), caused by PRF1 variants. Specifically, we evaluated the clinical significance of the frequent PRF1 A91V variant, if present in trans with a predicted loss-of-function (pLOF) PRF1 variant, defined as "disease mutation" listed in the Human Gene Mutation Database. We combined clinical and functional data from our hemophagocytic lymphohistiocytosis (HLH)-network registry with UK Biobank data to evaluate disease penetrance and clinical outcomes. Among 52 individuals with A91V/pLOF genotype in the registry, 39 (72%) showed FHL2-related manifestations with mean onset at 20 years. Four patients had recurrent disease, 15 received transplantation, and 14 died. Among 14 individuals with A91V/pLOF genotype identified by family screening (mean age, 29 years), however, only 1 was symptomatic. Moreover, among 21 A91V/pLOF carriers identified in 200 000 UK Biobank participants, 12 with genotypes identical to symptomatic registry patients, none had developed HLH by age 73 years. Premature stop pLOF alleles appeared more penetrant than missense variants, but functional data including perforin expression or cytotoxicity failed to predict disease manifestation. Our combined registry and population-based approach reveals significant variability in disease penetrance and severity among PRF1 A91V/pLOF carriers, with no clear association between genotype, functional data, and clinical outcomes. This complexity illustrates the challenges of genetic screening and highlights the need for careful clinical decision-making regarding preemptive HSCT in asymptomatic carriers.
引用
- Wegehaupt O, Borisov O, Sieni E, et al. Beyond genotype: challenges in predicting disease risk for carriers of biallelic perforin variants. Blood. 2025. PMID: 40090000. doi:10.1182/blood.2024027954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。